Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
ConditionPancreatic Adenocarcinoma
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorCancer Trials Ireland
About this trial
This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN) criteria) pancreatic adenocarcinoma will receive dose-escalated hypofractionated DP-IMRT via Intensity Modulated Radiotherapy (IMRT) / Volume Modulated Arc Therapy (VMAT).
Eligibility criteria
Qualifiers
Written informed consent obtained prior to any study-related procedures
Age ≥18 years
ECOG (European Cooperative Oncology Group) performance status (PS) 0-2
Resectable or borderline resectable per National Comprehensive Cancer Network (NCCN) criteria (see Appendix H)
Disqualifiers
Previous thoracic or abdominal or pelvic radiation therapy (RT)
Previous treatment for bilirubin regression, other than stenting
Known co-existing or prior malignancy within the last 5 years (except for Basal Cell Carcinoma (BCC) or Squamous Cell Carcinoma (SCC) of the skin) which is likely to interfere with treatment or assessment of outcomes
Syndromes or conditions associated with increased radiosensitivity
Trial design
Treatments tested in this trial
- Dose-Painted Intensity Modulated Radiotherapy
Treatment groups
49 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov